Histamine H4 Receptor mediates interleukin-8 and TNF-α release in human mast cells via multiple signaling pathways

X-F. Chen¹, Z. Zhang², X. Dou², J-J. Li³, W. Zhang¹*, Y-Y. Yu³*, B. Yu¹,²*, 2*

¹ Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, Guangdong Province, China.
² Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong Province, China.
³ School of Medicine, Shenzhen University, Shenzhen 518060, Guangdong Province, China.

Abstract: Histamine, mainly produced by mast cells, is an important inflammatory mediator in immune response. Recently Histamine H4 Receptor (H4R) was also identified in mast cells, from which pro-inflammatory cytokines and chemokines are released. However, the mechanism of how H4R mediates these cytokines and chemokines release in mast cells was still unclear. To further explore the role of H4R in the immune inflammatory response in mast cells, we tested the release of inflammatory cytokine tumor necrosis factor-α (TNF-α), chemokine interleukin-8 (IL-8) and the relevant signaling pathways activated by H4R on LAD2 cells (a human mast cell line). We found that the release of IL-8 and TNF-α were blocked by inhibitors of PI3K, ERK and Ca²⁺-Calcineurin-NFAT signaling pathways, while the release of these cytokines and chemokines were enhanced by the inhibitor of P38 signaling pathway. However, inhibitors of the JNK and NF-κB signaling pathways had little effect on the expression of the pro-inflammatory mediators. Moreover, activation of the H4R could induce phosphorylation of ERK, p38 and AKT in mast cells. In conclusion, we found that H4R mediates the release of inflammatory cytokine TNF-α and chemokine IL-8 in human mast cells via PI3K, Ca²⁺-Calcineurin-NFAT and MAPKs signaling pathways.

Key words: Histamine, Histamine H4 receptor, Mast cells, IL-8, TNF-α.

Introduction

Histamine is a biogenic amine that plays an important role in many physiological processes (1). Histamine mediated multiple signaling pathways in inflammation and allergic responses via four G-protein-coupled receptors named H1R, H2R, H3R and H4R. H1R was a classical receptor that modulated inflammatory and allergic responses (2). However, the therapeudic inhibitors of H1R and H2R could not restrain all symptoms of inflammation and allergic diseases (3).

It was found that H4R was expressed in hematopoietic cells, and played an important regulatory role in the activation of mast cells, eosinophils, monocytes, dendritic cells, and T cells (4, 5). Mast cells activated by H4R can release lots of inflammatory mediators to trigger and amplify inflammatory cascade on chronic phase of immuno reactions. Because of its important roles in chronic inflammation and allergic symptoms, H4R was considered as a new therapeutic target for allergic inflammation diseases such as asthma and rhinitis (6-8).

Although researches on H4R signaling pathways have been mainly focused on cAMP and intracellular calcium levels, it was showed that Histamine H4 receptor activation enhances LPS-induced IL-6 production in mast cells via ERK and PI3K activation (9). What’s more, H4R activation led to induction of AP-1 in both dendritic cells and T cells (10, 11). Therefore, these reports put some insights into the downstream signaling pathways of the H4R.

LAD cell lines remain dependent upon stem cell factors for survival and proliferation, which express intracytoplasmic histamine, tryptase and chymase. H4R, expressed by mast cells including LAD2 cells and primary cord blood derived CD34+ human mast cells, plays a primary role in the progression of allergic inflammatory responses by enhancing the secretion of two important contributors, pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) and chemokine interleukin-8 (IL-8) (12-14). However, the relationship between these inflammatory protein release and the signaling pathways downstream of the H4R in mast cell remained unclear. In order to understand the mechanism of H4R on the activation of mast cells in allergic inflammation, we elucidated the H4R mediated functional activation of IL-8 and TNF-α in the human mast cells line LAD2 cells and related signal transduction pathways. Finally, it was found that H4R mediated the release of inflammatory cytokine TNF-α and chemokine IL-8 in human mast cells via PI3K, Ca²⁺-Calcineurin-NFAT and MAPKs signaling pathways.

Materials and Methods

Cell Culture and Reagents

The Laboratory of Allergic Disease 2 (LAD2) human
mast cells were kindly provided by A. Kirshenbaum and D. Metcalfe (NIH, USA) (15). Cells were maintained in StemPro-34 (Invitrogen, USA) medium as previously described (16). Clobenpropit was purchased from Sigma. PD 98059, SP 600125, SB 203580, Bay 11-7821, Ciclosporin were purchased from Tocris. Wortmannin was purchased from Cayman. When chemicals were dissolved in DMSO, the final concentration of DMSO did not alter the normal response of LAD2 cells.

**IL-8 and TNF-α measurement**

After pre-incubated with various inhibitors for the corresponding time periods, LAD2 cells were incubated with different concentrations (4×10^−5 M and 8×10^−5 M) of clobenpropit for overnight. The release of IL-8 and TNF-α in the supernatants were measured by ELISA assay (BD Biosciences, USA) according to the manufacturer’s instructions. The working concentrations of six inhibitors were determined as follows: PD 98059, 10μM; SP 600125, 20μM; SB 203580, 10μM; Bay 11-7821, 10μM; Ciclosporin, 2μg/ml; Wortmannin, 0.5μM.

**Western blotting**

Whole cell lysate of The LAD2 cells was in RIPA buffer, while nuclear and cytoplasmic proteins were extracted by Nuclear and Cytoplasmic Protein Extraction Kit (Sangon, China). The following steps of Western blotting were performed as previously described (17). The primary antibodies were as following: Anti-Akt (cell signaling, Beverly, MA); Anti-phospho-Akt (Ser 473, cell signaling, Beverly, MA); Anti-JNK (cell signaling, Beverly, MA); Anti-phospho-JNK (Thr 183/ Tyr 185, cell signaling, Beverly, MA); Anti-ERK (cell signaling, Beverly, MA); Anti-phospho-ERK (Thr 202/ Tyr 204, cell signaling, Beverly, MA); Anti-p38 MAPK (cell signaling, Beverly, MA); Anti-phospho-p38 MAPK (Thr 180/ Thr 182, cell signaling, Beverly, MA); Anti-NFAT (cell signaling, Beverly, MA); Anti-NF-κB (Abcam, USA), Anti-β-tubulin (ProteinTech, China) .Then a secondary antibody (1:1000 diluted) (MBL) was added on the membrane for 1 h at room temperature. After incubated in ECL solution (Pierce Chemical, Rockford, IL), levels of proteins were detected and analyzed by a LAS-1000 Pro image reader.

**Statistical analysis**

Statistical significance was determined by student t-test and one-way ANOVA. Significant differences were considered when P value was less than 0.05. All of the data were expressed as Means ±SEMs.

**Results**

**H4R agonist induced IL-8 and TNF-α production in human mast cells**

Mast cells have the ability to release various bioactive mediators such as cytokines and chemokines. Because IL-8 and TNF-α are considered as primary mediators of inflammatory responses, our effects on IL-8 and TNF-α production via H4R on mast cells were explored to further understand the mechanism of pro-inflammatory proteins release via H4R activation. Clobenpropit, one of H4R agonists, dose dependently induced IL-8 and TNF-α production in LAD2 cells (Fig.1A and Fig.1B). It suggested that H4R mediated the release of IL-8 and TNF-α in human mast cells.

**IL-8 and TNF-α release induced by H4R from activated LAD2 cells was inhibited by blockers of PI3K and Ca²⁺-Calcineurin-NFAT signaling pathways**

To find out the downstream signaling pathways of H4R activation which induce the release of IL-8 and TNF-α, LAD2 cells were treated with clobenpropit after pre-incubated with different signaling pathway inhibitors for 30 min. Activation of calcineurin contributes to the release of IL-8 and TNF-α (18, 19). As shown in Fig. 2A, IL-8 and TNF-α release induced by clobenpropit were dramatically blocked by ciclosporin, which is the specific inhibitor of calcineurin. PI3K is well known for its role in human mast cells activity in response to various cell surface receptors including H4R (20). Consistent with previous reports, we found wortmannin, the PI3K inhibitor, inhibited IL-8 and TNF-α release induced by clobenpropit (Fig. 2B). NF-κB was considered to participate in the production of cytokines and chemokines driven by histamine from activated microglia (21). However, the release of IL-8 and TNF-α induced via clobenpropit were not reduced after the addition of the NF-κB inhibitor Bay 11-7821 (Fig. 2C).

**Figure 1.** Effect of H4R agonist on IL-8 and TNF-α release from LAD2 cells. (A) The amount of IL-8 release from LAD2 cells incubated with the different concentrations of clobenpropit. (B) The amount of TNF-α release from LAD2 cells incubated with the different concentrations of clobenpropit. The levels of IL-8 and TNF-α spontaneous release and those in the present of H4R agonist were compared with one-way ANOVA and student t-test. *p<0.05, **p<0.01, ***p<0.001 (n = 3–5).
H4R mediates IL-8 and TNF-α release. X-F. Chen et al. 2016 | Volume 62 | Issue 1

Clobenpropit (Fig. 3B). What’s more, after the treatment of an inhibitor of JNK (SP600125), the release of IL-8 and TNF-α induced via clobenpropit were not changed (Fig. 3C).

Analysis of H4R induced activation of MAPKs, AKT, Ca²⁺-Calcineurin-NFAT and NF-κB in human mast cells

The fact that some inhibitors could affect H4R induced IL-8 and TNF-α production indicated that these pathways may take part in the H4R signaling pathways. To figure out the signaling pathways used by H4R, we have analyzed the key molecules in activation of MAPKs, AKT, Ca²⁺-Calcineurin-NFAT and NF-κB signaling pathways in LAD2 cells. LAD2 cells were pre-treated with clobenpropit, and the changes in phospho-
As Fig. 4A shown, clobenpropit clearly induced ERK phosphorylation in mast cells. Phosphorylated AKT is a representative for activation of the PI3K pathway. AKT phosphorylation could be also induced in LAD2 cells activated by H4R agonist (Fig. 4A). What’s more, H4R agonist was able to induce the phosphorylation of p38 in a time-dependent way in LAD2 cells.

Dephosphorylation of the transcription factor NFAT by the phosphatase calcineurin enables its nuclear translocation (22). As shown in Fig. 4B, clobenpropit clearly increased nuclear translocation of NFAT in these mast cells. What’s more, since there were no changes of IL-8 and TNF-α release from LAD2 cells incubated with the NF-κB inhibitor and JNK inhibitor, there were no obvious changes in the level of the NF-κB nuclear translocation and the JNK phosphorylation.

Discussion

Histamine activates mast cells via H4R, which triggers many immune and inflammatory responses (2). However, the biological function of histamine H4 receptor was not clear. IL-8 and TNF-α were associated with allergic symptoms and chronic inflammatory conditions. Therefore, our data clearly showed that activation of the H4R led to IL-8 and TNF-α production. The effects of the H4R on IL-8 and TNF-α production were consistent with previous findings by using another H4R agonist, 4-methylhistamine (14).

Based on the previous clinical studies, H4R is a promising target in chronic inflammatory conditions (23). Recently, it indicated H4R played a role in a powerful inflammatory cascade, though the underlying mechanisms were unclear. The previous findings suggested that both ERK and PI3K phosphorylation were required...
for the release of IL-6 via the activation of H4R on mast cells (9). The results shown here expanded on early reports of the H4R downstream signaling pathways (6, 10, 11, 24). Our data suggested that activation of PI3K, ERK, Ca²⁺-Calcineurin-NFAT and P38 signaling pathways were necessary for the IL-8 and TNF-α release induced via H4R in mast cells. The kinetics of ERK, p38, JNK and AKT activation are also important in many cellular functions. There are several reports indicating the involvement of these kinase pathways in downstream of H4R. Pretreatment with pertussis toxin essentially abolished the ability to induce phosphorylation of ERK in the cells transfected with the H4R (24). Phosphorylated ERK also took part in MMP-9 production in endothelial cells, and enhanced survival of mature B cells (25, 26). It suggested that there were differential roles between transient activation and sustained activation of the PI3K pathway (27). Changes in kinetics of these kinases may influence the resident time of them and the location of their associated transcription factors, which lead to changes of IL-8 and TNF-α release.

However, there were some opposite evidences existing. For example, histamine could not induce ERK phosphorylation and instead histamine receptor could activate the transcription factor AP-1 in dendritic cells (10). What’s more, p38 inhibitor seemed to partially inhibit phosphorylation of ERK in the cells transfected with pertussis toxin essentially abolished the ability to induce the phosphorylation of Akt, ERK and p38. (B) Effect of H4R agonist on subcellular location of NF-κB and NFAT in human mast cells. Mast cells were pretreated with clobenpropit for 30 min. Blots carried out on cytoplasmic protein and nuclear protein collected from LAD2 cells showed H4R activates NFAT signaling pathway.

Acknowledgements
We would like to thank the Shenzhen Biomedical Research Support Platform and the Shenzhen Molecular Diagnostic Platform of Dermatology for technical help. This work was supported by National Natural Scientific Foundation of China (81271755, 81371737, 81402600), Guangdong Natural Scientific Foundation (2014A030313708), Shenzhen Research Grant (CXZZ20140416144209739, JCYJ20150403110829622), and China Postdoctoral Science Foundation (2014M562195).

References
5. Schneider, E., Bertron, A.F. and Dy, M., Modulation of hematopoiesis through histamine receptor signaling. Front Biosci (Schol Ed). 2011, 3: 467-473. doi:
13. Dy, M. and Schneider, E., Histamine-cytokine connection in...


23. Neumann, D., Beermann, S. and Seifert, R., Does the histamine H4 receptor have a pro- or anti-inflammatory role in murine bronchial asthma? *Pharmacology.* 2010, **85**: 217-223. doi: 10.1159/000285088


